Cite
HARVARD Citation
Calafat Sard, M. et al. (n.d.). P634 Ustekinumab and vedolizumab as first-line biological therapy for inflammatory bowel disease. A multicenter study based on the ENEIDA registry. Journal of Crohn's and colitis. pp. i766-i767. [Online].